Unlike traditional launch plans designed for blockbuster products, oncology and hematology therapy commercialization requires agility.
- Different tumor types and the form of therapy require distinct commercialization strategies.
- Patients with lung, breast, or colon cancer often undergo long-term, multi-faceted treatment following early detection, requiring sustained patient services and financial support. In contrast, pancreatic cancer patients typically face urgent needs due to late-stage diagnosis.
At EVERSANA, we developed a life sciences commercialization model specific to product and patient needs using a system of archetypes that consider therapy type, how the product is administered and the impact of the therapy on the patient journey.
Leveraging our award-winning model commercialization model, coupled with our deep bench of oncology experts, EVERSANA ONCOLOGY partners with manufacturers to develop a customized, comprehensive go-to-market strategy. Click here to learn more about EVERSANA ONCOLOGY Commercialization®.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…